| Literature DB >> 28616244 |
Abstract
This review provides a concise summary of the changing phenotypes of macrophages and fibroblastic cells during the local inflammatory response, the onset of tissue repair, and the resolution of inflammation which follow injury to an organ. Both cell populations respond directly to damage and present coordinated sequences of activation states which determine the reparative outcome, ranging from true regeneration of the organ to fibrosis and variable functional deficits. Recent work with mammalian models of organ regeneration, including regeneration of full-thickness skin, hair follicles, ear punch tissues, and digit tips, is summarized and the roles of local immune cells in these systems are discussed. New investigations of the early phase of amphibian limb and tail regeneration, including the effects of pro-inflammatory and anti-inflammatory agents, are then briefly discussed, focusing on the transition from the normally covert inflammatory response to the initiation of the regeneration blastema by migrating fibroblasts and the expression of genes for limb patterning.Entities:
Keywords: amphibian limb regeneration; fibroblast; fibrosis; inflammation; macrophage; scar
Year: 2017 PMID: 28616244 PMCID: PMC5469729 DOI: 10.1002/reg2.77
Source DB: PubMed Journal: Regeneration (Oxf) ISSN: 2052-4412
Figure 1Macrophage activation phenotypes in tissue repair, regeneration, and fibrosis (reproduced with permission from Wynn and Vannella, 2016, Immunity 44: 450–62). Throughout inflammation and tissue repair in mammals, the activation states of resident macrophages and immigrating monocytes change to promote the tasks at hand, including angiogenesis, reformation of epithelial continuity, growth and differentiation of stem cells, and stimulation of widely ranging fibroblast activities. DAMP, damage‐associated molecular pattern; PAMP, pathogen‐associated molecular pattern; Treg cell, regulatory T cell; IRF5, interferon regulatory factor 5; NOS2, nitric oxide synthase 2; LXR, liver X receptor; AREG, amphiregulin; Arg1, arginase‐1; IRF4, interferon regulatory factor 4; PPARg, peroxisome proliferator‐activated receptor g; FGF, fibroblast growth factor; GAL‐3, galectin‐3; TGF, transforming growth factor; IC, immune complex; GR, glucocorticoid receptor; ATF3, activating transcription factor 3; SOCS, silencer of cytokine signaling
Summary of maximal cytokine levels detected in (from Brant et al., 2016, Wound Rep. Regen., 24: 75–88). Levels for each cytokine are shown by differing numbers of plus signs, with five maximum, one minimum. A minus sign indicates “absent”
| Cytokine |
|
|
|---|---|---|
| GM‐CSF | ++ | − |
| G‐CSF | +++++ | − |
| CCL1 | + | − |
| slCAM‐1/CD54 | ++++ | |
| IL‐2 | +++ | − |
| IL‐4 | + | − |
| IL‐6 | ++++ | − |
| IL‐7 | + | − |
| IL‐13 | + | − |
| CXCL10 | ++ | − |
| CXCL11 | + | − |
| CXCL1 | +++++ | − |
| M‐CSF | +++ | − |
| MCP‐5/CCL12 | ++ | − |
| MIG/CXCL9 | + | − |
| MIP‐1β | +++++ | − |
| TREM‐1 | ++++ | − |
| TIMP | ++++ | − |
| C5/C5a | +++++ | + |
| IL‐16 | ++ | + |
| MCP‐1/CCL2 | +++++ | + |
| MIP‐1α | +++++ | ++++ |
| MIP‐2 | +++++ | + |
| TNF‐α | ++ | + |
| CXCL13 | + | + |
| IFN‐γ | + | + |
| IL‐1α | ++ | ++ |
| IL‐1β | ++++ | ++++ |
| IL‐1ra | ++++ | ++++ |
| RANTES | ++ |
Figure 2Four‐millimeter ear punch closure in . 220×; scale bar is 1 mm. (Reproduced with permission from Matias Santos et al., 2016, Regeneration 3: 52–61)
Figure 3Effects of celecoxib on regeneration of developmental stage 54/55 . Treatment of larvae with 1 μM celecoxib, a cyclooxygenase‐2 (COX‐2) inhibitor, for 7 days post‐amputation allowed better patterning of regenerated limbs (A) than that of controls (B). (See King et al., 2012, Anat. Rec. 295: 1552−61, for similar quantitative data with this and other immunomodulating agents.) Importantly, improved patterning with celecoxib or other agents was not found with larvae at later developmental stages, consistent with the view that additional monocyte/macrophage growth and development beyond stage 54/55 may lead to a profibrotic inflammatory environment post‐amputation not reversible by COX‐2 inhibition